Transarterial Chemoembolization in Combination With Nivolumab Performed

Status Completed

Clinical Trial Summary

The IMMUTACE study evaluates the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) nivolumab in combination with transarterial chemoembolization (TACE) in patients with multinodular, intermediate stage hepatocellular carcinoma (HCC) as first line therapy.

Clinical Trial Description

Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers worldwide. The prognosis of patients with HCC is dismal and the mortality rates are almost the same as the incidence rates. The transarterial chemoembolization (TACE) is commonly used to act locally in the intermediate disease stage and is the most common first-line treatment in patients with HCC. Early randomized trials and more recent reviews and meta-analyses reported improved survival rates of patients with unresectable lesions managed with TACE so that TACE has been accepted as the standard treatment for intermediate stage disease. However, outcome of patients treated with TACE in real-life cohorts is still very poor with median overall survival (OS) of 20 months or less. In order to increase the outcome of TACE, several trials have analyzed the combination of TACE with sorafenib and other anti-angiogenic agents. However, none of the trials have reported an improved overall survival for patients treated with the combination of TACE and sorafenib. Early clinical data already support a safe combination of immune checkpoint inhibition with TACE. Moreover, preliminary data from the CheckMate-040 trial strongly suggest that nivolumab has clinical activity and is tolerable in patients with HCC, including those with hepatitis B or hepatitis C virus (HCV) infection. Therefore, the aim of this study is to evaluate the safety and efficacy of TACE in combination with nivolumab in patients with intermediate stage HCC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03572582
Study type	Interventional
Source	AIO-Studien-gGmbH
Contact
Status	Completed
Phase	Phase 2
Start date	June 14, 2018
Completion date	December 10, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03289533` - A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)	Phase 1
Terminated	`NCT01141478` - Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria	N/A
Recruiting	`NCT05580835` - PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma	N/A
Active, not recruiting	`NCT05389527` - Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT04560751` - TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Withdrawn	`NCT02939807` - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	Phase 2
Completed	`NCT01915602` - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2
Completed	`NCT04970212` - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting	`NCT02403544` - Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma	Phase 1
Completed	`NCT01897038` - A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma	Phase 1
Terminated	`NCT01337492` - Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)	Phase 0
Completed	`NCT01003015` - Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma	Phase 2
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Completed	`NCT00559455` - Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT00384800` - A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)	Phase 2
Terminated	`NCT00582400` - A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver	Phase 2
Completed	`NCT00056992` - Testing of ADI-PEG in Hepatocellular Carcinoma	Phase 2
Completed	`NCT02859324` - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)	Phase 1/Phase 2
Terminated	`NCT02439008` - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma — IMMUTACE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms